A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Active, not recruiting · Phase 1 · NCT05308654
Conditions: Relapsed/Refractory Multiple Myeloma
At a glance
- Research payments reported, 2025
- $338,765
- U.S. investigators named
- 14
- Sites paid
- 17
- Planned or actual enrollment
- 34
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-453 (drug), Dexamethasone (drug), Daratumumab (drug), Lenalidomide (drug)
- Dates
- Started 2022-05-17; completion 2025-12
- Results posted
- Not yet
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. ABBV-453 is an investigational drug being developed for the treatment of R/R MM. Part 1 will be a monotherapy dose escalation phase to determine the best dose of ABBV-453. In Part 2, participants are placed in 1 of 3 groups called treatment arms. Each group receives a different treatment. Approximately 28 to 48 adult participants in Part 1 and 150 to 312 adult participants in Part…
From ClinicalTrials.gov, last updated 2025-08-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $338,765 in research payments for this study in 2025 (78 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Muhamed Baljevic, M.D. Hematology · Little Rock, AR
- Bita Fakhri, M.D., M.P.H Hematology · Palo Alto, CA
- Michaela Liedtke, MD Hematology · Stanford, CA
- Carl Landgren, MD Hematology & Oncology · Miami, FL
- Hana Safah, MD Hematology & Oncology · Baton Rouge, LA
- Ralph V. Boccia, M.D. Hematology & Oncology · Bethesda, MD
- Matthew J. Pianko, M.D. Hematology · Ann Arbor, MI
- Shaji K. Kumar, M.D. Hematology · Rochester, MN
- Cristina Gasparetto, M.D. Infectious Disease · Durham, NC
- David D. Hurd, MD Medical Oncology · Winston-salem, NC
- Jonathan E. Lambird, M.D. Hematology & Oncology · Winston Salem, NC
- Saad Usmani, MD Internal Medicine · Charlotte, NC
- Peter M. Voorhees, MD Hematology · Charlotte, NC
- Dan T. Vogl, MD Hematology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloankettering Cancer Center $70,999
- Wake Forest University Health Sciences $50,296
- Carolinas Medical Center-Northeast, NC $48,201
- University of Michigan Health System, MI $42,956
- Duke University $37,581
- University of Miami $20,736
- Memorial Sloan Kettering Cancer Center $14,700
- Board of Trustees of the Leland Stanford Junior University $13,576
- Hospital of Univ of Pennsylvania, PA $11,480
- Vanderbilt University Medical Center, TN $7,816
- American Oncology PArtners PA $4,891
- Atrium Health Union, NC $4,200
- The Administrators of the Tulane Educational Fund $2,700
- Mayo Clinic $2,327
- Stanford University School of Medicine $2,100
- American Oncology Network LLC $2,100
- Wake Forest University Student Health Services $2,100
- $8
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.